597 related articles for article (PubMed ID: 11249653)
21. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
22. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
Schultze JL; Grabbe S; von Bergwelt-Baildon MS
Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836
[TBL] [Abstract][Full Text] [Related]
23. Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments.
Spagnoli GC; Ebrahimi M; Iezzi G; Mengus C; Zajac P
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):184-92. PubMed ID: 20205052
[TBL] [Abstract][Full Text] [Related]
24. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
25. Cancer immunogene therapy.
Yoshizawa H; Kagamu H; Gejyo F
Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
[TBL] [Abstract][Full Text] [Related]
26. [Technological advances in immuno-oncology: from fundamental concepts to patient immunological monitoring].
Chouaib S; Echchakir H; Angevin E; Guerra N; Kosmatopoulos K; Caignard A; Lim A; Baron V; Ferradini L; Mami-Chouaib F
Bull Cancer; 2001 Aug; 88(8):733-40. PubMed ID: 11578941
[TBL] [Abstract][Full Text] [Related]
27. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
28. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
29. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
Lissoni P; Brivio F; Fumagalli L; Messina G; Meregalli S; Porro G; Rovelli F; Vigorè L; Tisi E; D'Amico G
Anticancer Res; 2009 May; 29(5):1847-52. PubMed ID: 19443415
[TBL] [Abstract][Full Text] [Related]
30. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
31. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
32. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
33. A prospect on cancer immunology.
Kobayashi H
Hokkaido Igaku Zasshi; 1979 Nov; 54(6):549-77. PubMed ID: 397163
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial.
Kan N; Ohgaki K; Yamasaki N; Hori T; Nakayama N; Nio Y; Inamoto T; Hikasa Y
Nihon Geka Hokan; 1983 Nov; 52(6):841-53. PubMed ID: 6380446
[No Abstract] [Full Text] [Related]
35. [Telomerase, a universal target in immunotherapy strategies against tumor?].
Rousseau R; Soria JC
Bull Cancer; 2000 Dec; 87(12):895-901. PubMed ID: 11174119
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
37. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
38. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
39. Imaging the immune response to monitor tumor immunotherapy.
Wang Q; Ornstein M; Kaufman HL
Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
